FRATES JAMES M
SEC CIK 1235598 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | CFO | 233.6K | $101.2K | $3.68M | 28 | 2022-01-06 | 2026-09-10 |
Most active insiders at AMLX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Klee Justin B. | Co-CEO, Dir | — | $4.03M |
| 2 | Cohen Joshua B | Co-CEO, Dir | — | $4.03M |
| 3 | Mazzariello Gina | CLO | — | $1.18M |
| 4 | FRATES JAMES M | CFO | — | $708.4K |
| 5 | Bedrosian Camille L | Chief Medical Off | — | $689.0K |
| 6 | Firestone Karen | Dir | $152.2K | — |
| 7 | MILNE GEORGE M JR | Dir | — | — |
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-14 16:00 | 2026-09-10 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $32.36 | -10.8K | 233.6K | -4% | -$349.8K |
| 2026-08-20 21:00 | 2026-08-18 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +22.8K | 244.4K | +10% | $0 | |
| D | 2026-03-09 | 2026-03-05 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +96.0K | 261.6K | +58% | $0 |
| 2026-03-04 | 2026-03-02 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $14.52 | -7,909 | 165.6K | -5% | -$114.8K | |
| 2026-02-04 | 2026-02-02 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $14.65 | -3,557 | 173.5K | -2% | -$52.1K | |
| 2026-01-08 | 2026-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $11.11 | -3,326 | 177.1K | -2% | -$37.0K | |
| 2025-10-02 | 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $14.65 | -10.6K | 280.4K | -4% | -$154.7K | |
| 2025-04-02 | 2025-03-31 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $3.47 | -10.9K | 291.0K | -4% | -$37.8K | |
| D | 2025-03-10 | 2025-03-06 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +68.4K | 301.9K | +29% | $0 |
| 2024-09-16 | 2024-09-12 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | P - Purchase | $2.53 | +40.0K | 233.5K | +21% | +$101.2K | |
| DA | 2024-09-05 | 2023-08-23 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | M - OptEx | $6.88 | +18.2K | 73.8K | +33% | +$125.0K |
| D | 2024-04-18 | 2024-04-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +91.2K | 226.0K | +68% | $0 |
| 2024-03-07 | 2024-03-05 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $18.73 | -1,792 | 134.8K | -1% | -$33.6K | |
| D | 2024-02-28 | 2024-02-26 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +40.0K | 152.0K | +36% | $0 |
| 2024-01-11 | 2024-01-09 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $16.33 | -2,716 | 112.0K | -2% | -$44.4K | |
| I | 2023-11-02 | 2023-10-31 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | G - Gift | $0.00 | +11.1K | 11.1K | New | $0 |
| D | 2023-08-24 | 2023-08-23 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | M - OptEx | $6.88 | +18.2K | 106.3K | +21% | +$125.0K |
| D | 2023-05-18 | 2023-05-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | M - OptEx | $6.88 | +32.5K | 88.2K | +58% | +$223.6K |
| DM | 2023-05-18 | 2023-05-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale+OE | $26.94 | -32.5K | 55.7K | -37% | -$875.6K |
| DAI | 2023-04-26 | 2022-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | C - Cnv Deriv | $0.00 | +19.5K | 19.5K | New | $0 |
| DA | 2023-03-24 | 2023-03-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +21.7K | 55.7K | +64% | $0 |
| DMA | 2023-03-24 | 2023-03-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale+OE | $31.89 | -32.5K | 35.7K | -48% | -$1.04M |
| DA | 2023-03-24 | 2023-03-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | M - OptEx | $6.88 | +32.5K | 66.5K | +96% | +$223.6K |
| DM | 2023-03-20 | 2023-03-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $31.89 | -32.5K | 3,213 | -91% | -$1.04M |
| D | 2023-03-20 | 2023-03-16 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +21.7K | 23.2K | +1,436% | $0 |
| M | 2023-01-10 | 2023-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | S - Sale | $36.30 | +2,658 | 34.8K | +8% | +$96.5K |
| D | 2023-01-04 | 2022-12-30 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | M - OptEx | $6.88 | +5,000 | 36.7K | +16% | +$34.4K |
| D | 2022-01-10 | 2022-01-06 | AMLX | Amylyx Pharmaceuticals, Inc. | FRATES JAMES M | CFO | A - Grant | $0.00 | +31.7K | 31.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations